Dr. Regina DePietro cautions about untested 'research purposes' products, as a WashU survey finds only 30% of St. Louisans think GLP-1s are safe.
Recap by typeshit. Full story at The St. Louis American.
Both suppliers of compounded semaglutide and tirzepatide ingredients landed on the FDA import-alert list. Times Now also covers dosing mistakes with compounded vials.
Penn researchers stress the self-reports in JAMA Network Open don't prove the drug caused anything, but increased appetite topped the list despite trials pointing to nausea.
The visits came in the country's largest healthcare system, with the trend credited to wellness influencers and young people among those affected.
Researchers at the American Academy of Ophthalmology meeting found NAION patients on GLP-1 drugs tended to develop it in the other eye sooner.
The clinic reports more patients arriving on Ozempic, Wegovy or Mounjaro, and says the drugs' effects on the face now factor into surgical planning.
Bauer, who has a PhD in neuroscience and endocrinology, joins Geller to discuss insulin resistance and the shame many women feel about their weight.
Loading…